Trial Profile
A Phase II Randomized Multicenter Open Label Prospective Study of Neoadjuvant Chemotherapy Docetaxel With or Without MEK Inhibitor SELUMETINIB in Patients With Early and Locally Advanced Triple Negative Breast Cancer
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Selumetinib (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin
- Indications Breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 23 Feb 2016 New trial record